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Abstract: Although rare, male breast cancer (MBC) remains a substantial cause for  morbidity 
and mortality in men. Based on age frequency distribution, age-specific incidence rate  pattern, 
and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer 
(BC). Compared with female BC (FBC), MBC cases are more often hormonal receptor 
 (estrogen receptor/progesterone receptor [ER/PR]) positive and human epidermal growth factor 
 receptor 2 (HER2) negative. Treatment of MBC patients follows the same indications as female 
postmenopausal with surgery, systemic therapy, and radiotherapy. To date, ER/PR and HER2 
status provides baseline predictive information used in selecting optimal adjuvant/neoadjuvant 
therapy and in the selection of therapy for recurrent or metastatic disease. HER2 represents 
a very interesting molecular target and a number of compounds (trastuzumab [Herceptin®; 
F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb®, GlaxoSmithKline, London, 
UK]) are currently under clinical evaluation. Particularly, trastuzumab, a monoclonal antibody 
which selectively binds the extracellular domain of HER2, has become an important therapeutic 
agent for women with HER2-positive (HER2+) BC. Currently, data regarding the use of 
trastuzumab in MBC patients is limited and only few case reports exist. In all cases, MBC 
patients received trastuzumab concomitantly with other drugs and no severe toxicity above 
grade 3 was observed. However, MBC patients that would be candidate for trastuzumab therapy 
(ie, HER2+/ER+ or HER2+/ER− MBCs) represent only a very small percentage of MBC cases. 
This is noteworthy, when taking into account that trastuzumab is an important and expensive 
component of systemic BC therapy. Since there is no data supporting the fact that response 
to therapy is different for men or women, we concluded that systemic therapy in MBC should 
be considered on the same basis as for FBC. Particularly in male patients, trastuzumab should 
be considered exclusively for advanced disease or high-risk HER2+ early BCs. On the other 
hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 
and epidermal growth factor receptor, may represent an interesting and promising therapeutic 
agent for trastuzumab-resistant MBC patients.
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Introduction
Male breast cancer (MBC) is a rare disease compared with female breast cancer 
(FBC). However, its incidence is increasing. Similar to breast cancer (BC) in women, 
MBC is likely to be caused by the concurrent effects of different risk factors, includ-
ing  hormonal, environmental, and genetic risk factors. Compared with women, BC 
in men occurs later in life, is mostly represented by invasive ductal carcinoma with 
higher stage, lower grade and more likely expresses estrogen receptor (ER) and 
 progesterone receptor (PR) and less likely overexpresses human epidermal growth 
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factor  receptor 2 (HER2). In general, MBC resembles 
 postmenopausal  hormone  receptor positive FBC.1
Overall, MBCs are diagnosed with a more severe clinical 
presentation than in women and prognosis in male is worse 
than in female patients. BC mortality and survival rates 
have improved significantly over time for both male and 
female BC. Decline in MBC mortality rates would likely 
reflect the impact of adjuvant systemic treatments, since 
men did not receive screening mammography. Indeed, the 
improvement for male is smaller when compared with female 
patients, suggesting a delay or nonappropriate utilization of 
adjuvant therapy. To date, MBC treatment follows the same 
indications as female postmenopausal BC, with some minor 
variations.
Since its clinical introduction, trastuzumab (Herceptin®; 
F. Hoffmann-La Roche, Basel, Switzerland), a monoclonal 
antibody which selectively binds the extracellular domain 
of HER2, has become an important therapeutic agent for 
women with HER2-positive (HER2+) BC and has changed, 
in particular, clinical management of HER2 overexpressing 
advanced BC patients. Thus far, only few data have been 
reported about the role of trastuzumab in MBC patients.
In this review, we described the available information on 
MBC, with particular regard to epidemiological, genetic, and 
clinicopathologic aspects, and the current use of trastuzumab 
in FBC in order to shed some light on the possible use of 
trastuzumab in male patients with HER2+ BC.
Male breast cancer
epidemiology
In western countries, MBC makes up less than 1% of all 
cancers in men and its incidence seems to vary according 
to different geographical areas and ethnic groups.2–5 The 
worldwide variation of MBC resembles that of FBC, with 
higher rates in North America and Europe and lower rates 
in Asia. A substantial high incidence (from 5% to 15%) is 
reported in Africa6,7 where the relatively high rates have 
been attributed to endemic infectious diseases causing liver 
damage and leading to hyperestrogenisms. Jewish men 
are the ethnic group with a higher than average incidence 
(2/3 per 100,000 per year).8
Although rare, MBC appears to be increasing as reported 
by the Surveillance, Epidemiology and End Results (SEER) 
Program of the National Cancer Institute (NCI), and reviewed 
by the United Kingdom Association of Cancer Registries.1,9 
Data from the SEER database indicate that the incidence 
of MBC has been increasing during the last 30 years, from 
about 1 per 100,000 to around 1.2 per 100,000. The incidence 
of MBC increases steadily with age and, differently from 
the bimodal age frequency distribution seen in women, the 
age frequency distribution in men is unimodal with peak 
 incidence in the early seventh decade. Age-specific incidence 
patterns show that the biology of MBC may resemble that 
of late-onset postmenopausal FBC.10 Furthermore, similar 
BC incidence trends over time among men and women 
suggest that there are common BC risk factors that affect 
both sexes.11
MBCs are diagnosed at a more advanced age and with a 
more severe clinical presentation than in women, with greater 
tumor size, and a more frequent lymph nodes involvement.10 
The mean age of BC presentation in males is mostly in late 
60s, which is about 10 years greater than in female patients. 
The mortality and survival rates for MBC have improved in 
the general population over time.11 The overall 5- and 10-year 
survival rates of MBC patients are around 60% and 40%, 
respectively. No significant difference in terms of disease-free 
survival (DFS) or overall survival (OS) between female and 
male BC patients has been observed.11 BC mortality and sur-
vival rates have improved significantly over time for both male 
and female BC. However, the relative improvement was less 
significant for men compared with women. Decline in FBC 
mortality rates are attributed to adjuvant systematic therapy and 
screening mammography. Decline in MBC mortality would 
likely reflect just the impact of adjuvant systematic treatment 
since men do not receive screening mammography. Indeed, the 
improvement for male is smaller when compared with female 
BC patients, suggesting an underutilization or nonappropriate 
utilization of adjuvant therapy.
Risk factors
Similar to BC in women, MBC seems to be caused by 
the concurrent effects of different risk factors including 
clinical disorders relating to hormonal imbalances, specific 
 occupational/environmental exposures, and genetic risk 
 factors, particularly a positive family history (FH) of BC 
and mutations in BC predisposing genes, such as BRCA1/2 
and possibly others genes.
Hormonal imbalance between an excess of estrogen and 
a deficiency of testosterone represents one of the major risk 
factors related to MBC. This imbalance may occur endog-
enously due to testicular abnormalities, liver disease,  obesity, 
Klinefelter’s syndrome, and gynecomastia.  Conditions 
increasing exposure to estrogen or decreasing exposure to 
androgen, such as the long-term use of antiandrogens and 
estrogens in the treatment of prostate cancer, the exogenous 
administration of estrogen to trans-sexuals or abuse of 
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 steroids for physical performances have also been implicated 
as causative factors for MBC.12–14
With regard to occupation and environmental risk factors, 
occupational exposure to heat and electromagnetic radia-
tion seems to be associated with MBC risk. As in women, 
ionizing radiations have been considered as possible causal 
cofactors in the etiology of MBC.15 Overall, environmental 
factors, particularly occupational carcinogen exposure, might 
contribute to MBC risk by interacting with genetic factors. 
Indeed, we observed a strong association between a specific 
occupation (truck driving) and BC risk in male carriers of 
BRCA1/2 mutations.16
Similar to FBC, a positive FH of BC is associated with 
increased risk of MBC. About 20% of all MBC patients have 
a history of BC in first-degree female relatives. A positive 
FH of either female or male BC among first-degree relatives 
confers a 2- to 3-fold increase in MBC risk.17–23 The risk raises 
with increasing number of first-degree relatives affected and 
with early onset in affected relatives. A personal history of a 
second primary tumor is reported in more than 11% of MBC 
patients.24 Men diagnosed with a first primary BC have a 
16% increased risk of developing a second primary cancer 
in comparison with the general male population.24 Data 
from the SEER program from the NCI show that a history 
of MBC is associated with a 30-fold increased risk of BC 
on the contralateral side, which is much higher than the 2- to 
4-fold increase observed in women.25,26
The major genetic risk factor for MBC predisposition is 
represented by germ-line mutations in BRCA2 and with lower 
frequency, BRCA1 genes. The frequency of BRCA1 and BRCA2 
mutations is different in ethnically diverse population and clini-
cally based MBC series, ranging from 4% to 40% for BRCA2 
and up to 10% for BRCA1, resulting higher in the presence of 
founder effects.27,28 BRCA1 and BRCA2 founder mutations have 
been identified in specific countries or ethnic groups, particularly 
in genetically isolated populations such as the Icelanders and 
Ashkenazi Jews. However, even in heterogeneous countries, 
such as Italy, there is evidence of founder BRCA1 and BRCA2 
mutations in regions that show microhomogeneity.29–35
Overall, BRCA1 and BRCA2 mutations are more preva-
lent in men with a positive first-degree FH compared with 
those without.17,36,37 Although BRCA2 mutations are  currently 
considered as the major genetic risk factor for MBC, there 
is no evidence for a correlation between the location of 
the mutation within the gene and MBC risk. Notably, the 
median age at BC diagnosis among BRCA2 mutation  carriers 
is earlier (median, 58.8 years) than that of negative cases 
(median, 67.9 years).17
Clinicopathologic characteristics  
and treatment
The predominant histological type of BC in men is inva-
sive ductal carcinoma, which represents about 90% of 
all male breast tumors.38 Much rarer tumor types include 
invasive papillary and medullary carcinoma and Paget 
disease.32,39,40 Since the male breast lacks terminal lobules, 
unless it is exposed to high doses of endogenous and/or 
exogenous estrogens, the lobular histotype accounts only for 
about 2% of invasive cancers.27,38 The lobular histotype has 
been reported in association with Klinefelter’s syndrome and 
rarely, in genotypically normal men with no previous history 
of estrogen exposure or gynecomastia.41 Ductal carcinomas 
in situ are rare and comprise about 10% of BC in men, 
whereas lobular carcinoma in situ has only been reported in 
association with invasive lobular carcinoma.38,42
MBCs express high levels of hormone receptors. 
 Compared with FBC, tumors in MBC are more likely to 
be ER (80%–90% vs 75%) and PR (73%–81% vs 65.9%) 
 positive. The proportion of hormone-receptor-expressing 
tumors increases with age, as occurs in postmenopausal 
women.38 The expression of androgen receptors ranges from 
39% to 95% according to various reports.43–45
Studies on HER2 expression in MBC are limited and 
with conflicting results, most likely due to different scoring 
systems and cut off values used. However, recent studies, 
performed by using both immunohistochemical (IHC) and 
fluorescence in situ hybridization (FISH) analyses, indicate 
that about 15% of MBCs showed HER2 overexpression.46,47 
Overall, overexpression of HER2 is less likely to be pres-
ent in MBC than in FBC.48,49 Overexpression of HER2 is a 
well-known prognostic factor associated with poor survival 
in women with BC. However, data regarding the association 
between HER2 overexpression and survival are still limited 
and contrasting in MBC.
Compared with women, BCs in men occur later in life, are 
mostly invasive ductal carcinomas with higher stage, lower 
grade and are more often ER+ and HER2 negative (HER2−) 
tumors. In general, prognosis in male is worse than in female 
patients, probably because of advanced stage at diagnosis 
together with higher age of male patients, often leading to 
the coexistence of serious comorbidities.
Recently, IHC markers have been used to classify BC 
in five molecular classes: luminal A (ER+ and/or PR+, 
HER2−), luminal B (ER+ and/or PR+, HER2+), basal-like 
(ER−, HER2−, CK5/6+, or HER1+), HER2+/ER−, and 
unclassified (negative for all markers).50 The role and the 
relevance of these five BC subclasses in MBC patients are 
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still largely unknown. A recent study, based on 42 MBC 
cases, showed that the luminal A subtype was the most 
common profile (83%) in MBC, whereas basal-like and 
HER2+/ER− BCs were not identified.46 Notably, the HER2+/
ER− subtype associates with a worse prognosis in FBC. This 
may raise questions on the correlation in prognosis, as well 
as in response to therapy, of BC in males and females, since 
frequency of BC subtypes between FBC and MBC seems to 
be different. The luminal B subtype was observed in 17% of 
MBCs and tended to have high nuclear grade and more fre-
quent epidermal growth factor receptor (EGFR) expression. 
Furthermore, BC patients with luminal B subtype showed 
nodal involvement more frequently.
Overall, due to age frequency distribution, age-specific 
incidence rate pattern, and prognostic factor profiles, MBC 
is considered similar to postmenopausal FBC51 and with 
some minor variations, MBC treatment follows the same 
indications as female postmenopausal BC.
To date, because there have been few clinical trials on 
treatment of MBC, most oncologists base their treatment 
recommendations on their personal experience with the 
disease and on the results of studies of BC in women. Par-
ticularly, tumor response for metastatic MBC has shown a 
similar behavior and similar predictive/prognostic factors as 
for postmenopausal FBC.27,52 As in females, BC in males can 
spread to the liver, lungs, and bones.
In men with hormone-dependent BC, tamoxifen and aro-
matese Inhibitors have been used and can increase survival to 
the same extent as in women with BC. Responses are gener-
ally similar to those seen in women with BC. Particularly, 
tamoxifen (standard treatment in ER+ disease) has shown its 
beneficial effect in visceral dominant, bone dominant, and 
soft tissue dominant metastasis and the response depends on 
ER% positivity.53,54
Systemic chemotherapy can be used in failed hormonal 
therapy or in ER− patients. In this setting, a study reported 
response rates of 67% for 5-fluorouracil, doxorubicin, 
and cyclophosphamide; 55% for doxorubicin and vin-
cristine; 53% for cyclophosphamide, 33% for cyclophos-
phamide, methotrexate, and 5-fluorouracil; and 13% for 
5-fluorouracil.55
HER2
HER2 is a member of the epidermal growth factor family 
(ErbB family) that consists of four transmembrane tyrosine 
kinase receptors: ErbB1 (EGFR/HER1), ErbB2 (HER2), 
ErbB3 (HER3), and ErbB4 (HER4). These transmembrane 
receptors are characterized by an extracellular  ligand- binding 
domain, an α-helical transmembrane domain, and an 
 intracellular tyrosine kinase regulatory domain that contains 
conserved sequences that are subject to autophosphoryla-
tion and phosphorylation by heterologous protein kinases 
(Figure 1).56,57
ErbB receptors normally exist as inactive monomers, 
ligand binding to the extracellular domain stabilizes the 
formation of active dimers (Figure 2). Dimerization can 
occur between two different ErbB receptors or between two 
domains of the same receptor and results in kinase domain 
activation, leading to transphosphorylation of tyrosine 
residues within the domains. Phosphorylation on tyrosine 
residues creates binding sites for adaptor or effector proteins 
containing Src-homology (SH2) and phosphotyrosine-
binding domains.56,58 The phosphatidylinositol-3-kinase 
(PI3K) and the mitogen-activated protein kinase (MAPK) 
pathways are two important signaling pathways activated 
by ErbB receptors (Figure 2). These pathways activate gene 
transcription resulting in proteins involved in cell prolifera-
tion, migration, differentiation, and apoptosis.58
HER2 has an active tyrosine kinase domain but it has 
no known extracellular ligand. Rather, it is a coreceptor 
that heterodimerizes with other activated ErbB receptor. 
HER2 is the preferred heterodimerization partner of all other 
ErbB receptors, increasing their ligand binding affinity.59,60 
Heterodimers containing HER2 are more stable than other 
heteromeric ErbB combinations, and consequently signaling 
from HER2 heterodimers is probably more powerful and 
enduring than from other ErbB combinations.61
Several types of human cancer, including BC, are asso-
ciated with deregulation of ErbB signaling due to gene 
amplification and/or protein overexpression. Amplification 
of HER2 gene produces protein levels up to 100 times 
greater than the normal one and the increased overexpres-
sion of HER2 protein may lead to increased homodimers 
and heterodimers of HER2, causing constitutive activation.62 
HER2 amplification and overexpression are reported in more 
than 25% of FBC.62–64 HER2 gene amplification and protein 
overexpression correlate with breast tumor size, high-tumor 
grade, lymph nodes involvement, high cell proliferation rate, 
aneuploidy, and lack of ER and PR.57 Furthermore, an inverse 
association between HER2 expression and long-term survival 
has been reported in women affected by BC.65
Somatic mutations of HER2 gene have been found in BC 
with an incidence of about 4%. The great majority of HER2 
mutations occur in exons 18–23, particularly exons 19 and 22, 
encoding the kinase domain.63 Interestingly, a specific splic-
ing variant of HER2 (∆HER2), which causes loss of exon 
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16 encoding the extracellular domain, has been identified in 
9% of BC overexpressing HER2 protein.66,67
HER2 is a well-known prognostic factor associated 
with poor survival in FBC; by contrast, the association 
between HER2 overexpression and survival is still debated 
in MBC.49,68,69 However, in MBC HER2 overexpression has 
been associated with specific phenotypic characteristics 
indicative of aggressive behavior, including high-tumor grade 
(G2, G3) and stages 3 and 4.39,40,69–71
To date, HER2 BC status provides baseline predictive 
information used in selecting optimal adjuvant/neoadjuvant 
therapy and in the selection of therapy for recurrent or 
metastatic disease.
Targeting HER2: trastuzumab
Trastuzumab (Herceptin) is a humanized immunoglobulin 
G1 (IgG1) kappa monoclonal antibody, which consists of 
two antigen-specific sites that selectively bind, with high 
affinity, the extracellular domain of the human HER2 recep-
tor.72 Trastuzumab, developed by the Genentech Corporation 
(South San Francisco, CA, USA), is produced by recombinant 
DNA technology in a mammalian cell (Chinese hamster 
ovary) culture.73,74 It inhibits the proliferation of BC cells that 
overexpress HER2 protein and mediates antibody-dependent 
 cell-mediated cytotoxicity on HER2 overexpressing cells.72 
There are several possible mechanisms, not completely 
understood, by which trastuzumab may act in decreasing 
HER2 signaling (Figure 3). Both preclinical and pilot clinical 
studies indicate a cytotoxic role for trastuzumab. The IgG1 Fc 
structure of the antibody may recruit Fc-competent immune 
effector cells, in particular natural killer cells, leading to 
the activation of antibody-dependent cellular  cytotoxicity. 
This event causes the lysis of cancer cells bound to tras-
tuzumab.75–77 Trastuzumab may reduce HER2 signaling 
by physically impeding either HER2 homodimerization or 
heterodimerization with other HER family partners and by 
inhibiting HER2 proteolytic cleavage that occurs when HER2 
is overexpressed, thus preventing the formation of a truncated 
membrane-bound phosphorylated fragment (p95) which 
can constitutively activate signal-transduction pathways.78,79 
Furthermore, trastuzumab may reduce the signaling from 
PI3K-Akt and MAPK pathways by the internalization and 
degradation of HER2 receptor.80 Trastuzumab specifically 
inhibits cell proliferation by reducing phosphatase and tensin 
homolog (PTEN) tyrosine phosphorylation and increasing 
PTEN membrane localization and phosphatase activity 
PTK
HER1
ECD
TD
ICD
HER2 HER3 HER4
LR
Ligand Ligand Ligand
CR
LR
CR
Tyrosine
phosphorylation
sites
Figure 1 HeR family receptors. epidermal growth factor family (erbB) receptors are characterized by an extracellular domain (eCD), consisting of two Leu-rich ligand-
binding subdomains (LR) and two Cys-rich subdomains (CR), a α-helical transmembrane domain and a intracellular domain (iCD), comprising the catalytic protein tyrosine 
kinase subdomain (PTK) and multiple regulatory tyrosine residues which become phosphorylated on receptor activation. The crosses on the human epidermal growth factor 
receptor 2 (HeR2) ligand-binding domains indicate their lack of functionality and on HeR3 protein tyrosine kinase subdomain indicate that it is catalytically inactive.
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and by inducing cell cycle arrest, during the G1 phase, by 
the accumulation of the cyclin-dependent kinase  inhibitor 
p27.81,82 Trastuzumab can also affect angiogenesis by down-
regulating specific proangiogenic factors such as vascular 
endothelial growth factor, transforming growth factor α 
(TGFα), plasminogen activator inhibitor-1, and angio-
poietin 1, and by upregulating antiangiogenic  factors as 
 thrombospondin 1.83
The variety of mechanisms in which trastuzumab is 
involved may give rise to several mechanisms of resis-
tance developed early or during treatment in HER2+ BCs. 
First, HER2 heterodimerization with other HER receptors 
can result in an incomplete inhibition and in an increased 
 signaling. On the other hand, an excess of ligands of HER1, 
HER3, and HER4, including TGFα, can interfere with 
 trastuzumab and lead to cell growth.84 Mutations in HER2 
or in HER2 targets, such as PI3K, might also be involved in 
trastuzumab resistance. Mutations in exon 21 of HER2 seem 
to play a role in the development of therapeutic resistance to 
trastuzumab in metastatic BC.85 Mutated PI3K produces a 
complex disruption that does not inhibit Akt, thus explain-
ing why trastuzumab may be ineffective in some tumors.86 
In PTEN-deficient breast tumors, Akt remains constitutively 
active and efficacy of trastuzumab is impaired.87  Trastuzumab 
binds an epitope on HER2, which can be masked by MUC4, 
a membrane associated glycoprotein. Studies on trastuzumab-
resistant cell line demonstrated that levels of MUC4 were 
inversely correlated with the trastuzumab binding capacity 
of single cells.88 Furthermore, Insulin-like growth factor-1 
receptor (IGF-1R) expression has been associated with an 
early progression of HER2+ BC and with a lower  trastuzumab 
response rate compared with tumors without expression of 
Cell proliferation
MAPK
PI3K
HER1, HER3,
HER4
Ligand
HER2
SOS
P P
RAF
RAS
mTOR
Akt
MEK
Cell migration
Cell differentiation and apoptosis
Figure 2 HeR2 pathway. Ligand binding to the extracellular domain of human epidermal growth factor receptor (HeR1/3/4) stabilizes the formation of active HeR2 
heterodimers. Transphosphorylation of tyrosine residues within the intracellular domains results in kinase domains activation. Phosphorylation creates binding sites for 
adaptor or effector proteins (SOS and Pi3K) that activate mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (Pi3K)-Akt pathways. These pathways 
result downstream in transcription of genes driving cell proliferation, migration, differentiation, and apoptosis.
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IGF-1R.89 Preclinical studies showed that the presence of 
HER2/IGF1-R heterodimers makes trastuzumab unable to 
bind to HER2 and to block cell proliferation.90
Trastuzumab and clinical relevance
Since its clinical introduction, trastuzumab has become an 
important therapeutic agent for patients with HER2+ BC. 
In a prospective trial, woman with metastatic disease was 
randomized to receive either chemotherapy alone (doxoru-
bicin/cyclophosphamide [AC] or paclitaxel [P]) or the same 
chemotherapy and trastuzumab. Patients treated with chemo-
therapy plus Herceptin had an OS advantage as compared 
with those receiving chemotherapy alone (25.1 months vs 
20.3 months, P = 0.05).
Herceptin received US Food and Drug Administration 
approval in 1998 for use in women with HER2+ metastatic 
BC. In this setting, actually, it is indicated for treatment of 
patients both as a first-line therapy, in combination with 
chemotherapy (ie, paclitaxel), and as a single agent in second/
third-line therapy.91
Recently, four large studies (HERA, BCIRG-006, NSABP 
B-31, and NCCTG N9831) have consistently demonstrated 
that Herceptin prolongs survival in woman with HER2 
 positive early BC.92–94
To date, Herceptin is the only targeted biologic agent 
approved for treatment of HER2+ BC in the adjuvant settings. 
Particularly, trastuzumab is used as adjuvant therapy for 
HER2+ (HER2 gene amplification by a FISH method or 
scored as 3+ by an IHC method) cancers to reduce the risk of 
recurrence when the tumor measures larger than 1 cm across 
or when the cancer has spread to the lymph nodes.
Trastuzumab in advanced breast  
cancer patients
Trastuzumab was able to change the clinical management 
of HER2 overexpressing metastatic BC. Both trials with 
trastuzumab alone or in combination with taxanes induced 
clinical benefit. To date, the gold standard for first-line treatment 
of HER2+ metastatic BC is represented by trastuzumab and 
chemotherapy (i.e. taxane combination).91–94 This statement is 
based on the evidences deriving from the pivotal randomized 
combination trials of trastuzumab (H0648g and M77001), 
which demonstrated a superior clinical benefit when trastu-
zumab plus a taxane is confronted with a taxane alone.
The H0648g trial enrolled 469 HER2+ metastatic BC 
women unpretreated for advanced disease. All clinical end 
points achieved improvement from the combination of 
trastuzumab with paclitaxel or with an anthracycline plus 
NK cell
HER2
Trastuzumab
A B C D
Trastuzumab
No cleavage
Costitutively
active p95
Internalization and degradation
P
Trastuzumab
Trastuzumab
Heterodimerization Cleavage
Figure 3 Mechanisms of action of trastuzumab. A) Trastuzumab may cause immune activation by recruiting natural killer (NK) cells, leading to cancer cells lysis. 
B) Trastuzumab may physically block either human epidermal growth factor receptor 2 (HeR2) homodimerization or heterodimerization with other HeR family partners. 
C) Trastuzumab may inhibit the shedding of HeR2 extracellular domain, preventing the formation of p95. D) Trastuzumab may reduce the signaling from downstream 
pathways by the internalization and degradation of HeR2.
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cyclophosphamide over paclitaxel or an anthracycline plus 
cyclophosphamide alone.93 Of patients receiving trastuzumab 
plus an anthracycline plus cyclophosphamide, 28% experi-
enced a cardiac event, compared with only 9.6% receiving 
an anthracycline plus cyclophosphamide alone. Of patients 
receiving trastuzumab plus paclitaxel, 13% experienced a car-
diac event, compared with 1% receiving paclitaxel alone. For 
this reason, the combination of trastuzumab with an anthra-
cycline plus cyclophosphamide is not currently indicated 
for clinical use.95 If we only consider the trastuzumab plus 
paclitaxel combination, a higher objective response rate (49% 
vs 17%), longer time to progression (TTP), and response 
duration (6.9 months vs 3.0 months and 10.5 months vs 4.5 
months) were observed.
In women showing HER2 3+ IHC expression, a 
median survival time of 25 months was reached with 
trastuzumab vs 18 months without trastuzumab.96 Outcomes 
were also improved by the addition of trastuzumab to pacli-
taxel in IHC HER2 3+ patients relative to the overall patient 
population (IHC 2+ and 3+).
The M77001 trial investigated, in the same setting of 
patients, the combination of weekly trastuzumab plus weekly 
or 3-weekly docetaxel. The median OS time was significantly 
higher with trastuzumab plus docetaxel than with docetaxel 
alone (31.2 months vs 22.7 months), even if 57% of patients 
documented crossover. All clinical outcomes investigated, 
including the median duration of response (11.4 months vs 
5.1 months) and median time to disease progression (TTP; 
10.6 months vs 5.7 months), were superior for trastuzumab 
plus docetaxel vs docetaxel alone.92
Because other trastuzumab-containing regimens may 
be required for patients who are not candidates for taxane-
based treatments, further combinations have been studied. 
Combinations of trastuzumab standard schedule with agents 
such as vinorelbine, gemcitabine, and capecitabine achieved 
interesting results.97
Currently, only few case reports exist about the use of 
 trastuzumab in MBC patients, and in all cases, patients 
received Herceptin concomitantly with other drugs (chemo-
therapy or hormonal agents).98
A first case report, published in 2001, described a 52-year-
old man with ER+, PR+, and HER2+ locally recurrent BC 
treated with radical mastectomy after three preoperative 
courses of epirubicin and cyclophosphamide. After surgery, 
he received radiotherapy and sequential chemotherapy 
with epirubicin and cyclophosphamide, finally the patient 
received tamoxifene. Experiencing progression for lung and 
bone metastases, the second-line chemotherapy included 
paclitaxel and trastuzumab, achieving a complete response 
of the lung metastases. A partial clinical response and good 
clinical benefit were obtained 9 months after the initiation 
of trastuzumab therapy.
Recently, Carmona-Bayonas99 reported a case of 
a metastatic MBC who achieved a complete response 
lasting .6 months with trastuzumab and anastrazole. 
The case was a 40-year-old man with ER+ and HER2+ 
BC treated with modified radical mastectomy. When he 
developed bone metas tases, received radiotherapy and 
sequential chemotherapy with epirubicin and cyclophosph-
amide, experiencing progression for lung and liver metas-
tases after five courses.  Second-line chemotherapy included 
docetaxel and trastuzumab, achieving a complete response of 
the lung metastases, and partial response of the liver lesions. 
Then, anastrozole and trastuzumab maintenance therapy was 
begun and continued until progression. A complete response 
lasting 11 months was obtained with an excellent quality of 
life. At further progression time, he received fulvestrant and 
trastuzumab for 4 months with stable disease.
Another recent study of Hayashi et al100 reported a case 
of advanced HER2+ MBC with lung metastases, which 
showed a good response to concomitant treatment of weekly 
trastuzumab and paclitaxel. The case was a 78-year-old man 
with ER−, PR−, and HER2+ BC. The patient was treated with 
weekly trastuzumab and paclitaxel. He experienced a partial 
response and trastuzumab was continued as maintenance 
therapy. His quality of life was improved and no severe 
adverse events above grade 3 were observed.100
Overall, in these case reports, no severe toxicity above 
grade 3 was observed.
According to NCI and National Comprehensive Cancer 
Network guidelines in MBC systemic therapy should be 
considered on the same basis as for a woman with BC since 
there is no data supporting the fact that response to therapy 
is different for men or women. Particularly, adjuvant trastu-
zumab should be considered exclusively for high-risk HER2+ 
MBC (Figures 4 and 5).101,102 However, patient preference is a 
major component of the decision-making process, especially 
in situations in which survival data are less among the avail-
able treatment options.
Trastuzumab as adjuvant therapy  
in early breast cancer patients
The clinical efficacy of trastuzumab in early BC was evalu-
ated in four large randomized clinical trials and one smaller 
randomized Finnish trial: the Breast International Group 
Herceptin Adjuvant (HERA), Breast Cancer International 
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Surgery
Operable breast cancer
ER positive and/or PR positiveER negative and PR negative
HER2 negative HER2 positive HER2 negative HER2 positive
CT + HT + trastuzumab1HT ± CTCT + trastuzumab1CT
Figure 4 Proposed algorithm for the treatment of operable male breast cancer.
Abbreviations: eR, estrogen receptor; PR, progesterone receptor; HeR2, human epidermal growth factor receptor 2; CT, chemotherapy; HT, hormonal therapy. 
Note: 1T $ 1 cm/N+; Levels of evidence, there is insufficient evidence to support the use of trastuzumab in early male breast cancer.
LABC
Neoadjuvant CT ± trastuzumab1 Neoadjuvant HT2 ± trastuzumab1
CT ± HT ± trastuzumab1
Operable
or
Inoperable
Surgery
ER positive and/or PR positiveER negative and PR negative
HER2 negative HER2 positive HER2 negative HER2 positive
CT + HT + trastuzumab1HT ± CTtrastuzumab1
Figure 5 Proposed algorithm for the treatment of locally advanced (inoperable) male breast cancer. 
Abbreviations: LABC, locally advanced breast cancer; CT, chemotherapy; HT, hormonal therapy; eR, estrogen receptor; PR, progesterone receptor; HeR2, human 
epidermal growth factor receptor 2.
Note: 1HeR2-positive tumors; 2eR positive and/or PR positive; Levels of evidence, there is insufficient evidence to support the use of trastuzumab or neoadjuvant CT in male 
breast cancer setting.
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Research Group (BCIRG)-006, the NSABP B-31,  Intergroup 
N9831, and Finnish FinHer trial.103–105 All these trials included 
HER2+ invasive BC patients radically resected by lumpec-
tomy or mastectomy. Both node positive or high-risk node-
negative patients were enrolled. All patients were to receive 
adjuvant chemotherapy and appropriate radiotherapy and 
hormonal therapy.
The HERA trial compared every-3-weeks trastuzumab 
for 1 year or 2 years with no trastuzumab in patients with 
HER2+ early BC who were radically resected and received 
at least four cycles of approved regimens of neoadjuvant or 
adjuvant chemotherapy. The patients treated with 1 year of 
trastuzumab vs observation showed a statistically significant 
36% reduction in disease recurrence (HR = 0.64; 3-year 
DFS of 81% vs 74%). OS was also significantly improved 
by 1-year trastuzumab (HR = 0.66; 92% vs 90% in the 
 trastuzumab and non-trastuzumab arms).104
The FinHer trial randomized patients to receive three 
cycles of docetaxel or vinorelbine followed by three cycles 
of fluorouracil, epirubicin, and cyclophosphamide. The 
study was designed to compare docetaxel and vinorelbine. 
However, the HER2+ BC patients were further randomized 
to receive or not receive 9 weeks of trastuzumab during the 
delivery of docetaxel or vinorelbine. Significantly improved 
DFS was found among those who received trastuzumab (89% 
vs 78%; P = 0.01) with a trend toward better OS (96% vs 
90%; P = 0.07).103
Updated results from these trials were presented at st Gal-
len consensus conference 2009 and continued to demonstrate 
the relevant role of trastuzumab-based treatment for patients 
with HER2+ disease.
The BCIRG-006 trial evaluated three regimens as adju-
vant systemic therapy after radical surgery. Doxorubicin and 
cyclophosphamide followed by trastuzumab plus docetaxel 
chemotherapy (AC-TH), docetaxel and carboplatin plus 
trastuzumab (TCH), and AC followed by docetaxel alone 
(AC-T) as the control arm. An interim analysis of one-third 
of the required number of events showed that a significant 
improvement of DFS in both trastuzumab arms as compared 
with the control arm (HR = 0.49 and 0.61 for AC-TH and 
TCH, respectively). Results from the third analysis of BCIRG 
006 showed that patients with HER2+ breast tumors assigned 
to trastuzumab had a DFS as good as, or better than, that of 
patients assigned to anthracycline-based chemotherapy. There 
were 214 DFS events in the TCH group (HR = 0.75; 95% CI: 
0.63–0.90) vs 257 in the ACT group and 185 in the AC-TH 
group (HR = 0.64; 95% CI: 0.58–0.78). There were 113 deaths 
in the TCH group (HR = 0.77; 95% CI: 0.60–0.99) vs 141 
in the ACT group and 94 in the AC-TH group (HR = 0.63; 
95% CI: 0.48–0.81). However, no significant advantage was 
reported for DFS in the AC-TH arm compared with TCH; 
finally, 21 congestive heart failures (CHF) were reported in 
the AC-TH group vs four in the TCH group.
The NSABP B-31 trial compared four cycles of AC fol-
lowed by four cycles of every-3-week paclitaxel (P; ACP) 
with the same regimen plus 1 year of weekly trastuzumab 
(H)  beginning with the first cycle of P.105
The N9831 trial compared three arms: four cycles of AC 
 followed by 12-weekly doses of paclitaxel with the same 
regimen plus 1 year of H beginning after P in the second arm 
and beginning with the first P cycle in the third arm. In an 
intent-to treat analysis, there was a highly significant 52% 
reduction in the risk of disease recurrence with sequential 
trastuzumab (3-year DFS, 87% vs 75%; HR = 0.48), and a 
33% reduction in the risk of death (3-year OS, 94.3% vs 
91.7%; HR = 0.67).105
Overall, data regarding the indications for trastuzumab in 
male patients is limited. In particular, the activity of trastu-
zumab in HER2 overexpressing metastatic MBC remains to 
be established, and in adjuvant setting, there is no data about 
the efficacy or safety of this drug.
Tolerability profile of trastuzumab
Herceptin is given as an injection into a vein (IV), usually once 
a week (loading dose, 4 mg/kg as a 90 minutes of infusion and 
maintenance dose, 4 mg/kg as a 30 minutes of infusion) or at 
a larger dosage once every 3 weeks (loading dose, 8 mg/kg as 
a 90 minutes of infusion and maintenance dose, 6 mg/kg as a 
30 minutes of infusion). Trastuzumab follows a nonlinear but 
dose-dependent pharmacokinetic profile. Clearance decreases 
and T
1/2 
(28.5 days) increases with increasing dose.
The metabolism of trastuzumab is not fully understood, 
but it appears that the elimination of drug would involve 
clearance of IgG through the reticuloendothelial system. 
Trastuzumab was generally well tolerated in clinical trial 
for adjuvant treatment.105,106 Compared with other anti-
cancer drugs, the side effects of trastuzumab are relatively 
mild. They may include fever and chills, weakness, nausea, 
vomiting, diarrhea, and headache.107,108 During the first infu-
sion with trastuzumab, fever and/or chills, up to 40%, are 
observed in patients. These side effects are less common 
after the next dose.
A more serious potential side effect is heart damage 
leading to CHF. Cardiotoxicity of any grade occurs in 4% 
(3% class 3/4) of patients who receive trastuzumab as a 
single agent. Symptoms of severe cardiotoxicity may include 
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dyspnea, increased cough, paroxysmal nocturnal dyspnea, 
and peripheral edema. The risk of heart problems is higher 
when trastuzumab is given with certain chemotherapy drugs 
such as doxorubicin or epirubicin. Because of this increased 
frequency, combined therapy with an anthracycline is not 
recommended. The risk of cardiac dysfunction associated 
with trastuzumab therapy may be increased in older patients, 
patients with preexisting cardiac disease, and patients who 
have had prior cardiotoxic therapy or radiation therapy to 
the chest area. To date, cardiac assessment is mandatory 
at baseline and 3-monthly throughout treatment. The UK 
National Institute for Health and Clinical Excellence advises 
against the administration of trastuzumab to women with a 
left ventricular ejection fraction (LVEF) of #55%, a history 
of documented CHF, high-risk uncontrolled arrhythmias, 
angina pectoris requiring medication, clinically significant 
valvular disease, evidence of transmural infarction on ECG 
or poorly controlled hypertension. Cardiotoxicity associated 
with trastuzumab typically responds to medical therapy 
(diuretic, angiotensin-converting enzyme inhibitors, or 
digoxin) but may be severe and lead to cardiac failure with 
mural thrombi and stroke.109
The HERA trial highlighted the adverse effects of every-
3-weeks trastuzumab for 1 year after adjuvant chemotherapy 
observed in $5% of patients. These effects included arthralgia 
(8%), back pain (5%), nasopharyngitis (8%), fatigue (8%), 
peripheral edema (5%), pyrexia (6%), chills (5%), diarrhea 
(7%), nausea (6%), headache (10%), and cough (5%).105 In 
the same trials, trastuzumab group patients experienced higher 
frequency of severe CHF, symptomatic CHF, and confirmed 
significant LVEF decline than in the observation group. Four 
percent of trastuzumab-treated patients needed to discontinue 
treatment because of cardiac disorders. Recovery of cardiac 
function was obtained within 6 months in most patients.110
A higher incidence of cardiac toxicity in the trastuzumab 
arm was also reported in the NSABP B-31 trial. At 3-year 
follow-up, the relative risk of a cardiac event in trastuzumab-
treated patients was 5.9 (P , 0.0001). CHF was more 
frequent in older patients and those with a borderline LVEF 
following anthracycline therapy.111
The N9831 trial showed that cumulative incidences at 
3 years of cardiac events (CHF or cardiac death) in the groups 
receiving trastuzumab with paclitaxel (n = 570), trastuzumab 
after paclitaxel (n = 710) or chemotherapy alone were 3.3% 
and 2.8% vs 0.3%, respectively. This study also found an 
increased risk of a cardiac event in patients with older age 
($60 years), the prior or current use of antihypertensive 
agents, and an LVEF of ,55% at baseline.112
emerging options in trastuzumab-
resistant breast cancer patients
HER2 represents a very interesting molecular target and a 
number of other compounds have been developed and are 
currently evaluated in clinical trials. Lapatinib (Tykerb®) is 
a novel oral dual tyrosine kinase inhibitor that targets EGFR 
and HER2, both overexpressed in a considerable percentage 
of BCs. Results from recent studies in female metastatic BC 
showed that the combination of lapatinib plus letrozole as a 
first-line treatment regimen provided a significant improve-
ment in delaying disease progression when compared 
with treatment with letrozole alone. Moreover, lapatinib 
therapy was shown to prolong the TTP and increase the rate 
of response to capecitabine in patients who had received 
anthracycline-based and taxane-based chemotherapy, and 
whose tumors had progressed on trastuzumab. However, to 
date, there is no data on the role of lapatinib in MBC set-
ting. Taking into account the synergistic effect of lapatinib 
and hormone therapy and considering that EGFR may play a 
relevant role in MBC, this drug might represent an interesting 
and promising therapeutic agent for trastuzumab-resistant 
MBC patients.113 Pertuzumab is another recombinant human-
ized monoclonal antibody that is specifically designed as a 
HER2 dimerization inhibitor. Since Pertuzumab and trastu-
zumab bind different subdomains of the HER2 extracellular 
domain, combinational therapy of these two antibodies may 
be proposed since they act synergistically in inhibiting BC 
cell growth.114
Conclusions
Monoclonal antibodies such as trastuzumab have become 
important yet expensive components of systemic BC therapy. 
Preoperative systemic therapy is commonly used in women 
with locally advanced BC. In particular, in HER2+ female 
locally advanced BC, trastuzumab should be offered as neo-
adjuvant treatment alongside chemotherapy and after surgery, 
continued as adjuvant treatment.
So far, there is no data regarding the neoadjuvant 
trastuzumab-based treatment in MBC setting. However, in 
neoadjuvant or metastatic setting, trastuzumab-based therapy 
can be considered on the same basis as for a woman with 
BC since there is no data supporting the fact that response 
to therapy is different for men or women.
With regard to adjuvant setting, to date, there is no estab-
lished standard therapy for HER2+ MBC patients. Given 
the high cost and safety data, adjuvant trastuzumab should 
be considered investigational and exclusively for high-risk 
HER2+ MBC cases. In addition, particular attention should 
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be used in older patients with preexisting cardiac disease and 
patients who have had prior cardiotoxic therapy or radiation 
therapy to the chest area.
From a practical point of view, considering the finite 
resources that most health systems face, it should be consid-
ered that trastuzumab-containing regimens are expensive. In 
this context, it is noteworthy that MBC represents a very rare 
disease taking into account that MBC patients candidate for 
trastuzumab therapy (ie, HER2+/ER+ or HER2+/ER− MBCs) 
would represent only a very small percentage of MBC cases 
(0.0015% of all BC). Thus, similar to other rare diseases that 
have specific reimbursement policies providing full medicine 
refund, trastuzumab can be considered an “orphan drug” for 
the treatment of HER2+ MBC.
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